You searched for "investigation"
BPS – a diagnostic enigma
This article from a London teaching hospital presents the results of a Medline search about challenges in bladder pain syndrome. All the known definitions from the American Urological Association (AUA), European Association of Urology (EAU), etc. are given while the...Read all about it Mar/Apr 2018
It can be awkward when a patient asks you about a report in their favourite tabloid detailing an amazing research breakthrough or a ‘cutting-edge’ new treatment / test and you don’t know what they are talking about! So this section...Men with a susceptibility to prostate cancer: implications of family history in PCa risk-prediction
Incorporation of family history (FH) status into prostate cancer (PCa) risk stratification has the potential to underpin many aspects of PCa care. This group of men presents a unique challenge in early cancer detection, particularly given that most men without...Update on immunotherapy for non-muscle invasive transitional cell carcinoma of the bladder
Patients with high-risk non-muscle invasive bladder cancer (NMIBC) that have failed Bacillus Calmette-Guérin (BCG) treatment are a difficult group to treat, and many may not be suitable for the preferred treatment option of radical cystectomy. Bladder-preserving treatments for BCG-unresponsive high-risk...Sepsis syndrome in urology
There are approximately 100,000 cases of sepsis per year in the UK, of which 37,000 result in death (this is more than prostate cancer, breast cancer, HIV / AIDS and road traffic accidents combined). Urosepsis is defined as sepsis caused...
BCG strain differences have an impact on clinical outcome in bladder cancer immunotherapy
Bacillus Calmette-Guérin (BCG) has been part of the treatment algorithm for non-muscle invasive bladder cancer (NMIBC) for a number of years. In this single centre, prospective, randomised trial, two of the most commonly available strains, BCG Connaught and BCG Tice,...
A phase II dose-ranging study of mirabegron in patients with OAB
This was a multinational, multicentre, randomised, double–blind, double-dummy, parallel group placebo- and active- controlled phase II study. The study enrolled 1108 men and women aged 18 and over. The criteria were: patients must have had overactive blader (OAB) symptoms for...Recent advances in the management of castration resistant prostate cancer
Castrate resistant prostate cancer (CRPC) is defined by disease progression despite androgen-deprivation therapy lowering testosterone to castrate levels. It may present as a rise in serum levels of prostate specific antigen (PSA), progression of pre-existing disease, or the appearance of...Intelligent triage: improving outpatient efficiency
Background Improving outpatient (OP) efficiency and service structure is of paramount importance as the NHS seeks to manage ever increasing demand in the wake of the COVID-19 pandemic. As we re-establish services and attempt to clear the backlog, new ways...
Cardiac failure and medical therapy for LUTS / BPH
Alpha blockers (AB), 5-alpha reductase inhibitors (5-ARI) and combination therapy are widely prescribed for lower urinary tract symptoms (LUTS) considered consequent to prostatic enlargement and are the mainstay of first-line therapy. This retrospective interrogation of a large population-based dataset of...Read all about it Jan/Feb 2017
It can be awkward when a patient asks you about a report in their favourite tabloid detailing an amazing research breakthrough or a `cutting-edge’ new treatment / test and you don’t know what they are talking about! So this section...
